SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will be presenting at the Jefferies Healthcare Conference being held on June 7-9, 2023 in New York City, NY.
| Event: | Jefferies Healthcare Conference |
| Date: | Thursday, 8 June 2023 |
| Time: | 10:00am – 10:25am (ET) |
A live webcast of Mr. Voigt’s presentation will be available here and after the conference under the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; This email address is being protected from spambots. You need JavaScript enabled to view it.
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.07 |
| Daily Change: | -0.03 -1.43 |
| Daily Volume: | 131,831 |
| Market Cap: | US$303.860M |
October 09, 2025 September 22, 2025 September 08, 2025 July 29, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
